Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05896956
Other study ID # CRGGCpros
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date July 1, 2023
Est. completion date June 30, 2027

Study information

Verified date June 2023
Source RenJi Hospital
Contact Xu-Heng Sun, PhD
Phone +86 19117209107
Email sunxh96@alumni.sjtu.edu.cn
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of the study is to establishing a standardized biobank and a clinical information database for patients with benign and malignant tumors of the biliary system. With follow-up plans and advanced multiomics technology, a multiomics database for patients with benign and malignant tumors of the biliary tract will be further established. Based on the above work, real-world clinical research on the diagnosis and treatment of biliary tract tumors is about to be carried out, and a high-standard cohort research foundation is laid for precision therapy based on multiomics characteristics and molecular typing of biliary tract tumors.


Description:

1. Trial population From the date of commencement of the study, patients who presented to the participating medical institutions in the study and were clinically diagnosed as benign or malignant tumors of the biliary system, and who met the inclusion criteria and did not meet any of the exclusion criteria, were enrolled in the study cohort after signing an informed consent form. Diagnostic criteria: Patients with benign biliary tumors and biliary malignant tumors diagnosed by pathology, and combined with clinical manifestations and imaging results, the first diagnosis and discharge were diagnosed as patients with advanced biliary malignant tumors. Inclusion Criteria: 1. Sign informed consent, have good compliance, and be willing to accept follow-up and provide blood samples 2. Age 18-74 years old, gender is not limited 3. Clinical diagnosis of benign and malignant tumors of the biliary system, including unoperated patients preliminarily diagnosed as benign and malignant tumors of the biliary tract according to the results of imaging examinations and laboratory tests, or pathological examination of patients treated with surgery confirmed as benign and malignant tumors of the gallbladder 4. The primary tumor is located in the extrahepatic bile duct, intrahepatic bile duct, gallbladder floor, gallbladder body, gallbladder neck or gallbladder duct 5. Karnofsky performance score greater than 50 Exclusion Criteria: 1. Patients with biliary malignant tumors, biliary malignant tumor foci are not primary lesions. 2. Patients with biliary malignant tumors, combined with serious central nervous system diseases, respiratory diseases, autoimmune diseases, chronic renal insufficiency and other diseases, long-term use of immunosuppressants, combined with serious uncontrolled infections 3. Patients with biliary malignant tumors, who also have active cardiovascular and cerebrovascular diseases, have cerebrovascular accidents, myocardial infarction, unstable angina pectoris, or grade II. or above congestive heart failure according to the standards of the New York Heart Association, and require serious arrhythmias requiring drug treatment 4. Patients with biliary malignant tumors, women of childbearing age who have a positive blood pregnancy test or have not had a pregnancy test, pregnant or breastfeeding women 5. The patient is participating in other therapeutic clinical trials where treatment measures cannot be clarified or treatment information cannot be collected 2. Sample size calculation In this study, based on the retrospective cohort statistics of CRGGC study, the average number of gallbladder cancer patients admitted to the hospital in previous years, and the proportion of gallbladder cancer to biliary malignant tumors in previous epidemiological investigations, the number of potential research subjects actually diagnosed and treated by each participating unit was estimated, and the study sample size was calculated. The number of cases of benign and malignant biliary tumors included in the cohort of benign and malignant tumors of the biliary tract in this study is expected to reach 60% of the total number of hospitalized patients admitted by the participating units every year, and it is expected that no less than 250 patients with benign and malignant tumors of the biliary tract will be enrolled every year, and 500 patients are expected to be enrolled within a baseline period of 2 years from the date of the start of the study. 3. Specific research content The target population of this study is patients with benign and malignant tumors of the biliary system, and the potential sample group is patients diagnosed with benign and malignant tumors of the biliary system in the participating medical institutions since December 31, 2022 and meet the criteria for inclusion and exclusion of the study, and based on the retrospective cohort statistics of the CRGGC study, the average number of patients with gallbladder cancer admitted to the hospital in previous years, as well as the proportion of gallbladder cancer to biliary malignant tumors in previous epidemiological investigations, the number of potential research subjects actually diagnosed and treated by each participating unit was estimated. Calculate the study sample size. The number of cases of benign and malignant biliary tumors included in the cohort of benign and malignant tumors of the biliary tract in this study is expected to reach 60% of the total number of hospitalized patients admitted by the participating units every year, and it is expected that no less than 250 patients with benign and malignant tumors of the biliary tract will be enrolled every year, and 500 patients are expected to be enrolled within a baseline period of 2 years from the date of the start of the study. This study cohort is a single-disease registry cohort, which does not involve grouping at the stage of establishing the registration cohort, but in the data analysis stage, it can be divided into different subgroups such as biliary malignant tumors, benign biliary tumors, gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma according to the diagnosis of the included patients. The research objectives of this study mainly include: (1) establishing a structured special disease dataset standard for biliary tumors based on the diagnosis and treatment norms and clinical pathways of biliary tract tumors; (2) Carry out clinical registration research on biliary tumors and build a special disease cohort; (3) Establish a biobank of biliary tumor cohort, including clinical diagnosis and treatment information such as patient diagnosis, surgery, treatment, progression, survival, and biological samples such as tumor tissue and body fluids; (4) Formulate standard operating specifications and sample quality control plans for the collection, transportation, acceptance, preparation, preservation and detection of biliary tumor biological specimen banks; (5) Formulate unified specimen bank management standards and information and data management processes, promote the intelligent management of specimen banks, and realize the linkage and integration of biobanks and specialized disease cohort databases; (6) Combine biliary tumor database, biomics technology, such as genomics, transcriptomics, proteomics, metabolomics technology, and big data acquisition, storage analysis technology to complete the molecular typing of biliary tumors. The outcome indicators of this study included overall survival time OS, recurrence-free survival time PFS, R0 resection rate of patients treated with biliary malignancy, and objective response rate ORR. The main measurement indicators of this study include the patient's demographic information, past history, life history, admission, preoperative examination information, surgery, postoperative situation, discharge, follow-up, outcome indicators, routine examination results of biological samples and multi-omics sequencing results, the above data are derived from the original records of prospective case questionnaires, the original records of patients' electronic medical records and the examination results of patients' biological samples. The outcome of follow-up was defined as patients having been followed up for five years, or having a patient lost to follow-up or dying during follow-up.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date June 30, 2027
Est. primary completion date June 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 74 Years
Eligibility Inclusion Criteria: 1. Sign informed consent, have good compliance, and be willing to accept follow-up and provide blood samples. 2. Age 18-74 years old, gender is not limited. 3. Clinical diagnosis of benign and malignant tumors of the biliary system, including unoperated patients preliminarily diagnosed as benign and malignant tumors of the biliary tract according to the results of imaging examinations and laboratory tests, or pathological examination of patients treated with surgery confirmed as benign and malignant tumors of the gallbladder. 4. The primary tumor is located in the extrahepatic bile duct, intrahepatic bile duct, gallbladder floor, gallbladder body, gallbladder neck or gallbladder duct. 5. Karnofsky performance score greater than 50. Exclusion Criteria: 1. Patients with biliary malignant tumors, biliary malignant tumor foci are not primary lesions. 2. Patients with biliary malignant tumors, combined with serious central nervous system diseases, respiratory diseases, autoimmune diseases, chronic renal insufficiency and other diseases, long-term use of immunosuppressants, combined with serious uncontrolled infections. 3. Patients with biliary malignant tumors, who also have active cardiovascular and cerebrovascular diseases, have cerebrovascular accidents, myocardial infarction, unstable angina pectoris, or grade II. or above congestive heart failure according to the standards of the New York Heart Association, and require serious arrhythmias requiring drug treatment. 4. Patients with biliary malignant tumors, women of childbearing age who have a positive blood pregnancy test or have not had a pregnancy test, pregnant or breastfeeding women. 5. The patient is participating in other therapeutic clinical trials where treatment measures cannot be clarified or treatment information cannot be collected.

Study Design


Intervention

Other:
no interventions
no interventions

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
RenJi Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival OS in patients with biliary malignancies was long-term follow-up data, defined as the primary endpoint, OS is calculated from the date of surgery for patients treated surgically, and OS is calculated from the date of diagnosis for patients treated non-surgically. The expected survival of patients with benign biliary tumors is longer, and this study does not select the study endpoint based on the follow-up of patients with benign biliary tumors, but mainly collects perioperative diagnosis and treatment data and collects biological samples. The last follow-up ended with the first of all patients followed up to death, loss to follow-up or withdrawal of informed consent, or follow-up for 2 years.
Secondary progression-free survival PFS was defined as a secondary endpoint. PFS is calculated from the date of surgery for patients treated surgically, and PFS is calculated from the date of diagnosis for patients treated non-surgically. The expected survival of patients with benign biliary tumors is longer, and this study does not select the study endpoint based on the follow-up of patients with benign biliary tumors, but mainly collects perioperative diagnosis and treatment data and collects biological samples. The last follow-up ended with the first of all patients followed up to death, loss to follow-up or withdrawal of informed consent, or follow-up for 2 years.
See also
  Status Clinical Trial Phase
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Terminated NCT00903396 - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Phase 2
Terminated NCT00896467 - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy N/A
Withdrawn NCT00386516 - Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer Phase 2
Completed NCT00033540 - S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Phase 2
Completed NCT00660699 - A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Phase 2
Terminated NCT04066491 - Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC Phase 2/Phase 3
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Recruiting NCT05489250 - The PLATON Network
Completed NCT00753675 - Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Phase 2
Completed NCT00304135 - Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Phase 2/Phase 3
Completed NCT00409864 - Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer N/A
Completed NCT00084942 - Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Phase 2
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Terminated NCT00658593 - Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer Phase 3
Completed NCT00486356 - Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer Phase 1
Not yet recruiting NCT06134193 - Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer Phase 2